Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
97 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape. Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 6 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology). - The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Sicca Syndrome (Sjogren) Overview 8 Therapeutics Development 9 Pipeline Products for Sicca Syndrome (Sjogren) - Overview 9 Pipeline Products for Sicca Syndrome (Sjogren) - Comparative Analysis 10 Sicca Syndrome (Sjogren) - Therapeutics under Development by Companies 11 Sicca Syndrome (Sjogren) - Therapeutics under Investigation by Universities/Institutes 13 Sicca Syndrome (Sjogren) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Sicca Syndrome (Sjogren) - Products under Development by Companies 17 Sicca Syndrome (Sjogren) - Products under Investigation by Universities/Institutes 18 Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development 19 Akari Therapeutics Plc 19 Amgen Inc 20 Ampio Pharmaceuticals Inc 21 Atlantic Bio Sci LLC 22 Biogen Inc 23 Bristol-Myers Squibb Company 24 Eli Lilly and Company 25 F. Hoffmann-La Roche Ltd 26 GlaxoSmithKline Plc 27 MedImmune LLC 28 Novartis AG 29 Redx Pharma Plc 30 Resolve Therapeutics LLC 31 Samjin Pharmaceutical Co Ltd 32 UCB SA 33 Sicca Syndrome (Sjogren) - Therapeutics Assessment 34 Assessment by Monotherapy Products 34 Assessment by Combination Products 35 Assessment by Target 36 Assessment by Mechanism of Action 38 Assessment by Route of Administration 40 Assessment by Molecule Type 42 Drug Profiles 44 abatacept - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ABS-11 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 AMG-557 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Ampion - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 belimumab - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 belimumab + rituximab - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 BIIB-063 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 BMS-986142 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 CDZ-173 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 CFZ-533 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Coversin - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 GSK-2618960 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 IMSO-001 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 lulizumab pegol - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 LY-3090106 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 MEDI-4920 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 MEDI-7734 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 RDX-002 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 RG-7625 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 RSLV-132 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 SA-001 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 seletalisib - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 VAY-736 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 VM-200 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Sicca Syndrome (Sjogren) - Dormant Projects 93 Sicca Syndrome (Sjogren) - Discontinued Products 94 Sicca Syndrome (Sjogren) - Product Development Milestones 95 Featured News & Press Releases 95 Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren's syndrome 95 Appendix 96 Methodology 96 Coverage 96 Secondary Research 96 Primary Research 96 Expert Panel Validation 96 Contact Us 96 Disclaimer 97
List of Tables
Number of Products under Development for Sicca Syndrome (Sjogren), H2 2016 9 Number of Products under Development for Sicca Syndrome (Sjogren) - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 12 Number of Products under Investigation by Universities/Institutes, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Sicca Syndrome (Sjogren) - Pipeline by Akari Therapeutics Plc, H2 2016 19 Sicca Syndrome (Sjogren) - Pipeline by Amgen Inc, H2 2016 20 Sicca Syndrome (Sjogren) - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 21 Sicca Syndrome (Sjogren) - Pipeline by Atlantic Bio Sci LLC, H2 2016 22 Sicca Syndrome (Sjogren) - Pipeline by Biogen Inc, H2 2016 23 Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Company, H2 2016 24 Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Company, H2 2016 25 Sicca Syndrome (Sjogren) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 26 Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H2 2016 27 Sicca Syndrome (Sjogren) - Pipeline by MedImmune LLC, H2 2016 28 Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H2 2016 29 Sicca Syndrome (Sjogren) - Pipeline by Redx Pharma Plc, H2 2016 30 Sicca Syndrome (Sjogren) - Pipeline by Resolve Therapeutics LLC, H2 2016 31 Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 32 Sicca Syndrome (Sjogren) - Pipeline by UCB SA, H2 2016 33 Assessment by Monotherapy Products, H2 2016 34 Assessment by Combination Products, H2 2016 35 Number of Products by Stage and Target, H2 2016 37 Number of Products by Stage and Mechanism of Action, H2 2016 39 Number of Products by Stage and Route of Administration, H2 2016 41 Number of Products by Stage and Molecule Type, H2 2016 43 Sicca Syndrome (Sjogren) - Dormant Projects, H2 2016 93 Sicca Syndrome (Sjogren) - Discontinued Products, H2 2016 94
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
